Compile Data Set for Download or QSAR
Report error Found 49 Enz. Inhib. hit(s) with all data for entry = 11758
TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM645122(US11872217, Compound 1.002)
Affinity DataIC50: 100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM645124(US11872217, Compound 1.004)
Affinity DataIC50: 100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM645131(US11872217, Compound 1.012)
Affinity DataIC50: 100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM645132(US11872217, Compound 1.013)
Affinity DataIC50: 100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM645126(US11872217, Compound 1.006)
Affinity DataIC50: 100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM645127(US11872217, Compound 1.008)
Affinity DataIC50: 100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM645128(US11872217, Compound 1.009)
Affinity DataIC50: 100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM645169(US11872217, Compound 1.051)
Affinity DataIC50: 100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM645165(US11872217, Compound 1.047)
Affinity DataIC50: 100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM645166(US11872217, Compound 1.048)
Affinity DataIC50: 100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM645167(US11872217, Compound 1.049)
Affinity DataIC50: 100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM645168(US11872217, Compound 1.050)
Affinity DataIC50: 100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM645153(US11872217, Compound 1.035)
Affinity DataIC50: 100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM645154(US11872217, Compound 1.036)
Affinity DataIC50: 100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM645155(US11872217, Compound 1.037)
Affinity DataIC50: 100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM645156(US11872217, Compound 1.038)
Affinity DataIC50: 100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM645149(US11872217, Compound 1.031)
Affinity DataIC50: 100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM645150(US11872217, Compound 1.032)
Affinity DataIC50: 100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM645151(US11872217, Compound 1.033)
Affinity DataIC50: 100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM645162(US11872217, Compound 1.044)
Affinity DataIC50: 100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM645163(US11872217, Compound 1.045)
Affinity DataIC50: 100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM645164(US11872217, Compound 1.046)
Affinity DataIC50: 100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM645157(US11872217, Compound 1.039)
Affinity DataIC50: 100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM645158(US11872217, Compound 1.040)
Affinity DataIC50: 100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM645160(US11872217, Compound 1.042)
Affinity DataIC50: 100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM645137(US11872217, Compound 1.018)
Affinity DataIC50: 100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM645138(US11872217, Compound 1.019)
Affinity DataIC50: 100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM645139(US11872217, Compound 1.020)
Affinity DataIC50: 100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM645133(US11872217, Compound 1.014)
Affinity DataIC50: 100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM645134(US11872217, Compound 1.015)
Affinity DataIC50: 100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM645136(US11872217, Compound 1.017)
Affinity DataIC50: 100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM645145(US11872217, Compound 1.026)
Affinity DataIC50: 100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM645146(US11872217, Compound 1.027)
Affinity DataIC50: 100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM645147(US11872217, Compound 1.028)
Affinity DataIC50: 100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM645148(US11872217, Compound 1.030)
Affinity DataIC50: 100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM645143(US11872217, Compound 1.024)
Affinity DataIC50: 100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM645144(US11872217, Compound 1.025)
Affinity DataIC50: 100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM645033(US11872217, Compound 1.001)
Affinity DataIC50: 5.05E+3nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM645123(US11872217, Compound 1.003)
Affinity DataIC50: 5.05E+3nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM645140(US11872217, Compound 1.021)
Affinity DataIC50: 5.05E+3nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM645135(US11872217, Compound 1.016)
Affinity DataIC50: 5.05E+3nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM645152(US11872217, Compound 1.034)
Affinity DataIC50: 5.05E+3nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM645129(US11872217, Compound 1.010)
Affinity DataIC50: 5.05E+3nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM645161(US11872217, Compound 1.043)
Affinity DataIC50: 5.05E+3nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM645130(US11872217, Compound 1.011)
Affinity DataIC50: 5.05E+3nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM645125(US11872217, Compound 1.005)
Affinity DataIC50: 5.05E+3nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM645141(US11872217, Compound 1.022)
Affinity DataIC50: 5.05E+3nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM645142(US11872217, Compound 1.023)
Affinity DataIC50: 5.05E+3nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM645159(US11872217, Compound 1.041)
Affinity DataIC50: 5.05E+3nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent